Research recently presented at the ASPC 2025 Congress on CVD Prevention sheds light on the heightened cardiovascular risks faced by patients with both rheumatoid arthritis (RA) and metabolic dysfunction-associated steatohepatitis (MASH). Dr. Rayan Salih from Northeast Georgia Health System highlighted how the coexistence of these conditions significantly increases the rates of non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI), heart failure exacerbation, arrhythmias, and stroke. The underlying culprit behind these elevated risks is believed to be inflammation, emphasizing the critical need for early and aggressive management in these high-risk individuals.
When examining the specific cardiovascular outcomes influenced by the synergistic effect of RA and MASH, the study focused on patients with MASH cirrhosis and those with RA, comparing them to individuals solely with MASH cirrhosis. Through propensity matching to align various factors and eliminate confounders, the analysis revealed a substantial increase in cardiovascular events in the group with both RA and MASH, encompassing STEMI, NSTEMI, heart failure exacerbation, arrhythmias, and strokes.
In dissecting the potential confounding variables contributing to this synergistic effect, the study meticulously matched demographics such as sex, age, race, and insurance status, alongside medications like disease-modifying agents, biological agents, GLP-1, and prednisone use. Common comorbidities that could trigger cardiovascular events were also balanced between the groups to ensure clean data. Notably, the study acknowledges limitations in assessing disease severity due to the reliance on the ICD-10 coding system.
The implications of these findings on risk stratification and holistic cardiovascular management in patients with RA and MASH are profound. While the observational nature of the study precludes establishing causality, the shared inflammatory milieu in both conditions likely drives the cascade of cardiovascular events. Identifying these individuals as high-risk mandates optimizing comorbidities, addressing risk factors comprehensively, and initiating early interventions with disease-modifying and biological agents. Moreover, lifestyle modifications including increased physical activity and healthier dietary habits should be integrated for a holistic approach to mitigating cardiovascular risks.
Key Takeaways:
- The synergy between rheumatoid arthritis and metabolic dysfunction-associated steatohepatitis significantly elevates cardiovascular risks.
- Propensity-matched analysis reveals a notable increase in cardiovascular events, emphasizing the need for early and aggressive management in high-risk patients.
- Meticulous matching of demographics, medications, and comorbidities underscores the multifaceted approach required for accurate data interpretation.
- Shared inflammatory pathways in RA and MASH underscore the importance of holistic management strategies to mitigate cardiovascular risks effectively.
Tags: immunotherapy
Read more on ajmc.com